• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Maze Therapeutics Inc.

    5/15/26 5:09:58 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MAZE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001676170
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Maze Therapeutics, Inc.
    SEC File Number
    001-42490
    Address of Issuer
    171 OYSTER POINT BOULEVARD, SUITE 300
    SOUTH SAN FRANCISCO
    CALIFORNIA
    94080
    Phone
    6508505070
    Name of Person for Whose Account the Securities are To Be Sold
    Coloma Jason V
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    UBS Financial Services Inc.
    Eleven Madison Avenue
    4th Floor
    New York � NY � 10010
    34502895326.905534526105/15/2026
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/22/2021GiftJason ColomaCheckbox checked11/01/2018259409/22/2021NA
    Common09/22/2021GiftJason ColomaCheckbox checked06/24/20193190809/22/2021NA

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    2,594 shares for this filing were sold under The Coloma 2021 Irrevocable Trust DTD 09/20/2021 and 31,908 shares were sold under Coloma Family Trust DTD 06/27/2016
    Date of Notice
    05/15/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    02/10/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ UBS Financial Services Inc., as attorney-in-fact for Jason Coloma as trustee

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MAZE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MAZE

    DatePrice TargetRatingAnalyst
    3/18/2026$68.00Buy
    Truist
    3/10/2026$97.00Outperform
    Mizuho
    12/4/2025$55.00Overweight
    Wells Fargo
    11/14/2025Outperform
    Raymond James
    9/2/2025$30.00Buy
    BTIG Research
    7/23/2025$34.00Buy
    H.C. Wainwright
    7/8/2025$17.00Outperform
    Wedbush
    More analyst ratings

    $MAZE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Maze Therapeutics with a new price target

    Truist initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $68.00

    3/18/26 8:23:36 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Maze Therapeutics with a new price target

    Mizuho initiated coverage of Maze Therapeutics with a rating of Outperform and set a new price target of $97.00

    3/10/26 8:41:33 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo initiated coverage on Maze Therapeutics with a new price target

    Wells Fargo initiated coverage of Maze Therapeutics with a rating of Overweight and set a new price target of $55.00

    12/4/25 8:45:11 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Coloma Jason V sold $725,495 worth of shares (27,858 units at $26.04) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

    6/24/26 4:14:54 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Spiegelman Daniel K

    4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

    6/10/26 4:31:33 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Scheller Richard H

    4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

    6/10/26 4:30:06 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Maze Therapeutics to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences: 2026 Jefferies Global Healthcare Conference in New York; presentation on Wednesday, June 3, 2026, at 3:45 p.m. ETGoldman Sachs 47th Annual Global Healthcare Conference 2026; presentation on Wednesday, June 10, 2026, at 8:40 a.m. ET Live webcasts of the events will be available in the Investors section of the Maze

    5/27/26 7:03:06 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

    Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027 Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026 Strong balance sheet with $528 million in cash, cash equivalents and marketable securities; inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026; cash runway expected to extend into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage b

    5/12/26 4:01:00 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maze Therapeutics Announces $150 Million Registered Offering

    SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions a

    4/22/26 12:09:44 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    SEC Filings

    View All

    SEC Form 8-K filed by Maze Therapeutics Inc.

    8-K - Maze Therapeutics, Inc. (0001842295) (Filer)

    6/10/26 4:15:18 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Maze Therapeutics Inc.

    144 - Maze Therapeutics, Inc. (0001842295) (Subject)

    6/1/26 4:16:56 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Maze Therapeutics Inc.

    8-K - Maze Therapeutics, Inc. (0001842295) (Filer)

    5/22/26 5:24:41 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    Leadership Updates

    Live Leadership Updates

    View All

    Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

    First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developin

    11/6/25 4:01:00 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. "I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics," said Mr. Hoppenot. "With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of M

    10/6/25 7:00:50 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    Financials

    Live finance-specific insights

    View All

    Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

    Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028 SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceu

    3/25/26 7:00:00 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

    – At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of AMKD patients with FSGS that were treated with MZE829 showed a 61.8% mean reduction in uACR – – Treatment of non-diabetic AMKD patients with MZE829 led to a clinically meaningful mean reduction in uACR from baseline of 48.6% – – Results provide first clinical proof-of-concept in genetically defined, broad AMKD population, including patients with moderate proteinuria and diabetes – – Maze plans to advance MZE829 to a pivotal program – – Maze to host investor conference c

    3/25/26 7:00:00 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

    Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective effect in CKD Well tolerated across all doses with an excellent safety profile and no serious adverse events observed Phase 2 trials in both PKU and CKD expected to initiate in 2026 Maze to hos

    9/11/25 7:30:00 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care